Amgen’s Phosphate Binder Loss May Be Genzyme’s Gain
This article was originally published in The Pink Sheet Daily
Once expected to plunder Renagel market share, AMG 223 suddenly gets left on the shelf.
You may also be interested in...
Sanofi Licenses Possible Renagel/Renvela Successor From Ardelyx
The French pharma paid an undisclosed amount for rights to a preclinical phosphate transport program, one of several non-absorbable drugs that act locally within the gut. The deal comes as market-leading Renagel and Renvela face imminent generic competition.
Biotech IPO Candidates Ramp Up To Get Out Before The Holidays
After a bit of a lull since September, there are seven biotechnology IPOs slated to get out in the next few weeks. But they are entering a tougher market than earlier in 2013, and some may not be quite the same quality.
Relypsa Adds Venture Funds In Another Effort To Reach Phase III
Relypsa, spun out from Amgen in 2007, has raised a third round of financing in an effort to move its lead compound into late-stage development.